CD14 Human Recombinant, CHO, CD14 Human, CHO, 50ug

CAT No.BT-PRO-536

CD14 Human Recombinant, CHO, CD14 Human, CHO, 50ug

---

Biological Activity
Up to 20 ug/ml CD14 inhibit binding of FITC-LPS (0.5ug/ml) to 6 x 105 CD14+CHO transfectants (FACS).

Description
The CD14 is produced from human CD14 transfected CHO-cells. Before transfection the complete human CD14-cDNA was amplified by PCR and cloned into expression vector p-POL-DHFR. The myeloid differentiation antigen CD14 acts as the major receptor for bacterial LPS. The dominant form of the recombinant wild type CD14 is the 50-kDa protein containing 335 amino acids.

Formulation
CD14 was lyophilized from a concentrated protein solution (1.0 mg/ml) containing phosphate-buffered saline, pH 7.2.

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity
Greater than 95.0% as determined by SDS-PAGE.

Solubility
It is recommended to reconstitute the lyophilized CD14 in sterile 18M¦¸-cm H2O not less than 100ug/ml. Further dilutions should be made with phosphate buffered saline (PBS).

Source
CHO-cells.

Stability
Lyophilized CD14 although stable at room temperature for 3 weeks, should be stored desiccated below -18¡ãC. Upon reconstitution CD14 should be stored at 4¡ãC between 2-7 days and for future use below
-18¡ãC.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.

Synonyms
Monocyte differentiation antigen CD14, Myeloid cell-specific leucine-rich glycoprotein, CD14.

Usage
TSZGENE's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.